MedPath

BioLab 612 LLC

🇷🇺Russia
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: Placebo
First Posted Date
2016-05-20
Last Posted Date
2016-07-20
Lead Sponsor
BioLab 612 LLC
Target Recruit Count
23
Registration Number
NCT02778763

Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer

Phase 2
Conditions
Colorectal Cancer
Interventions
Drug: Placebo
First Posted Date
2016-03-22
Last Posted Date
2017-02-09
Lead Sponsor
BioLab 612 LLC
Target Recruit Count
40
Registration Number
NCT02715882
Locations
🇷🇺

Federal State Budgetary Institution "State Scientific Center of Coloproctology named after A.N. Ryzhikh" Ministry of Health of the Russian Federation, Moscow, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath